A first of its kind vaccine for the deadly blood cancer acute myeloid leukaemia succeeded in a Phase 3 clinical trial, drugmaker Sellas Life Sciences and Memorial Sloan Kettering Cancer Center has announced.
A first of its kind vaccine for the deadly blood cancer acute myeloid leukaemia succeeded in a Phase 3 clinical trial, drugmaker Sellas Life Sciences and Memorial Sloan Kettering Cancer Center has announced.
www.mskcc.org/news/vaccine...
www.mskcc.org/news/vaccine...
go.nature.com/48aG0Dx
go.nature.com/48aG0Dx
www.mskcc.org/news/vaccine...
www.mskcc.org/news/vaccine...
Galinpepimut-S (GPS) trains the patient's own immune system to recognize and destroy cancer cells, rather than killing the cells directly like chemotherapy.
It reduces death from acute myeloid leukemia by 41%
www.biospace.com/drug-develop...
Galinpepimut-S (GPS) trains the patient's own immune system to recognize and destroy cancer cells, rather than killing the cells directly like chemotherapy.
It reduces death from acute myeloid leukemia by 41%
www.biospace.com/drug-develop...